Near-infrared photoimmunotherapy: a comparison of light dosing schedules

Oncotarget. 2017 May 23;8(21):35069-35075. doi: 10.18632/oncotarget.17047.

Abstract

Near infrared photoimmunotherapy (NIR-PIT) is a newly-developed cancer therapy in which a monoclonal antibody is conjugated to a near-infrared photoabsorber, IR700 to form an antibody photoabsorber conjugate (APC). After the APC binds to cancer cells expressing the cognate antigen, exposure to NIR light results in rapid, highly selective necrotic cell death of the cancer cells with minimal off-target effects. Several hours after NIR-PIT, the tumor vessels become supraphysiologically permeable and circulating APC can therefore readily leak into the already-treated tumor space where it can bind with viable cancer cells that is called super-enhanced permeability and retention effect. The presence of the SUPR effect after NIR-PIT has prompted regimens in which there is a repeat exposure of NIR light 24 hours after the initial NIR-PIT to take advantage of the leakage of additional APC deeper into the tumor. However, this post-treatment APC penetration was fully induced within 3 hours, therefore, it is possible that repeated exposures of NIR light could be administered much earlier than 24 hours and still produce the same effects. To test this idea, we compared several modes of delivering additional doses of light after initial NIR-PIT. We found that repeated exposures of NIR light starting 3 hours after initial NIR-PIT produced equal or superior results to more delayed exposures of NIR light. This finding has practical implications of an easy-to-perform regimen as repeated light exposures could be performed during a single day rather than extending the procedure over two days which is the current recommendation.

Keywords: cancer treatment; enhanced permeability and retention effect; monoclonal antibody; near infrared photoimmunotherapy.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Humans
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / pharmacology
  • Immunotherapy
  • Indoles / chemistry*
  • Isoindoles
  • Mice
  • Neoplasms, Experimental / drug therapy*
  • Panitumumab
  • Photochemotherapy
  • Photosensitizing Agents / chemistry*
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Indoles
  • Isoindoles
  • Photosensitizing Agents
  • Panitumumab
  • phthalocyanine